Search International and National Patent Collections
Some content of this application is unavailable at the moment.
If this situation persists, please contact us atFeedback&Contact
1. (WO1991008291) LATENCY ASSOCIATED PEPTIDE AND USES THEREFOR
Latest bibliographic data on file with the International Bureau

Pub. No.: WO/1991/008291 International Application No.: PCT/US1990/006292
Publication Date: 13.06.1991 International Filing Date: 30.10.1990
Chapter 2 Demand Filed: 13.06.1991
IPC:
A61K 38/00 (2006.01) ,A61K 38/18 (2006.01) ,A61K 38/20 (2006.01) ,A61K 38/21 (2006.01) ,C07K 14/495 (2006.01)
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
18
Growth factors; Growth regulators
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
20
Interleukins
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38
Medicinal preparations containing peptides
16
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17
from animals; from humans
19
Cytokines; Lymphokines; Interferons
21
Interferons
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
475
Growth factors; Growth regulators
495
Transforming growth factor (TGF)
Applicants:
GENENTECH, INC. [US/US]; 460 Point San Bruno Boulevard South San Francisco, CA 94080, US
Inventors:
LEVINSON, Arthur; US
HAMMONDS, Glenn, R.; US
MASON, Anthony; US
Agent:
HASAK, Janet, E. ; Genentech, Inc. 460 Point San Bruno Boulevard South San Francisco, CA 94080, US
ARMITAGE, Ian, M.; Mewburn Ellis & Co. York House 23 Kingway London WC2B 6HP, GB
Priority Data:
441,68022.11.1989US
Title (EN) LATENCY ASSOCIATED PEPTIDE AND USES THEREFOR
(FR) PEPTIDE ASSOCIE A LA LATENCE ET UTILISATIONS
Abstract:
(EN) An isolated nucleic acid sequence is provided that comprises a sequence that encodes a latency associated peptide having a molecular weight of about 75,000 when measured by non-reducing SDS-PAGE and capable of antagonizing a biological activity of mature TGF-$g(b), provided that the sequence does not also encode a mature TGF-$g(b). The latency associated peptide so produced is useful therapeutically in blocking a deleterious activity of an endogenously released or exogenously administered TGF-$g(b), alone or in combination with another exogenously administered or endogenously released immune regulator. It is also useful as a cotreatment therapy with mature TGF-$g(b), which forms a latent associated complex therewith that is activatable at the desired site $i(in vivo).
(FR) Une séquence d'acides nucléiques isolée comprend une séquence qui code un peptide associé à la latence ayant un poids moléculaire d'environ 75 000 lorsqu'on le mesure par SDS-PAGE de non réduction et peut être l'antagoniste d'une activité biologique de TGF-$g(b) mature, à condition que la séquence ne code pas également un TGF-$g(b) mature. Le peptide associé à la latence ainsi produit est utile en thérapie pour bloquer une activité délétère d'un TGF-$g(b) administré de manière exogène ou libéré de manière endogène, seul ou en combinaison avec un autre régulateur immun administré de manière exogène ou libéré de manière endogène. Il est également utile comme thérapie par cotraitement avec TGF-$g(b) mature, qui forme un complexe associé à la latence activable au niveau du site désiré $i(in vivo).
Designated States: AU, CA, JP
European Patent Office (AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, NL, SE)
Publication Language: English (EN)
Filing Language: English (EN)
Also published as:
EP0502036ES2083469JPH05503003CA2068204DE000069024369AU1990067440
DK0502036